Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | YWHAG | P61981 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053221 | 1.00 | RAB9A (0.46) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL12900615 | 0.87 | CYP4Z1 (0.46) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL14712149 | 0.85 | ALDH1A1 (0.53) | RAB9AALDH1A1KMT2ASMN1; SMN2PKM | |
| SCHEMBL13492095 | 0.84 | MEN1 (0.49) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL16340836 | 0.84 | CYP4Z1 (0.43) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL18524140 | 0.84 | MAPT (0.48) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL30192655 | 0.84 | CYP4Z1 (0.43) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL5156693 | 0.83 | SKP2 (0.49) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 | |
| SCHEMBL19675441 | 0.83 | ABL1 (0.43) | RAB9AALDH1A1KMT2ASMN1; SMN2PKM | |
| SCHEMBL15056738 | 0.83 | ABL1 (0.56) | RAB9AALDH1A1KMT2ACYP4Z1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032647-B | Lysophosphatidic acid receptor 1 (LPAR 1) inhibitor compounds | 伊莱利利公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2022-09-08 | — | — | US | disclosed |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-12-01 | — | — | US | disclosed |
| CN-107522634-B | Biaryl urea carboxylic acid derivative or salt thereof, and preparation method and application thereof | 复旦大学 | 2020-09-01 | — | — | CN | disclosed |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-07-23 | — | — | US | disclosed |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-07-23 | — | — | US | disclosed |
| EP-3679032-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-05-12 | — | — | US | disclosed |
| CN-111032647-A | Lysophosphatidic acid receptor 1(LPAR1) inhibitor compounds | 伊莱利利公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | FUDAN UNIVERSITY (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3476829-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | Fudan University (CN) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019041340-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046239-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046239-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR5 | RAB9A 1324/4885ALDH1A1 2519/4885KMT2A 1418/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | RAB9A 1324/4885ALDH1A1 2519/4885KMT2A 1418/4885 |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | RAB9A 526/4885ALDH1A1 655/4885KMT2A 1157/4885 |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | RAB9A 526/4885ALDH1A1 655/4885KMT2A 1157/4885 |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR3 | RAB9A 1255/4885ALDH1A1 2063/4885KMT2A 1607/4885 |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR3 | RAB9A 1255/4885ALDH1A1 2063/4885KMT2A 1607/4885 |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | RAB9A 504/4885ALDH1A1 644/4885KMT2A 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.